Advertisement

Topics

MorphoSys begins patient enrollment in phase 3 trial of gantenerumab to treat Alzheimer's disease

11:33 EDT 14 Jun 2018 | PharmaBiz

MorphoSys AG announced that the first patient has been enrolled in a new phase 3 trial of gantenerumab in patients with early Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against

Original Article: MorphoSys begins patient enrollment in phase 3 trial of gantenerumab to treat Alzheimer's disease

NEXT ARTICLE

More From BioPortfolio on "MorphoSys begins patient enrollment in phase 3 trial of gantenerumab to treat Alzheimer's disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...